Accepted for Publication: December 30, 2011.
Published Online: March 19, 2012. doi:10.1001/archneurol.2011.3758
Author Contributions:Study concept and design: Bernick, Cummings, Sun, and Aisen. Acquisition of data: Bernick, Cummings, and Aisen. Analysis and interpretation of data: Bernick, Cummings, Raman, Sun, and Aisen. Drafting of the manuscript: Bernick, Cummings, and Raman. Critical revision of the manuscript for important intellectual content: Bernick, Cummings, Raman, Sun, and Aisen. Statistical analysis: Raman and Sun. Administrative, technical, and material support: Bernick and Cummings. Study supervision: Bernick and Aisen.
Financial Disclosure: Dr Cummings has provided consultation to Abbott Laboratories, Acadia, Acerra, Adamas Pharmaceuticals, Anavex Life Sciences, Astellas Pharma, Avanir Pharmaceuticals, Baxter, Bristol-Myers Squibb, Eisai, Elan, EnVivo Pharmaceuticals, Forest Pharmaceuticals, Genentech, GlaxoSmithKline, Janssen Pharmaceuticals, Eli Lilly, Lundbeck, MedAvante, Medivation, Medtronic, Merck, Merz, Neurokos, Neuronix, Neurotrax, Novartis, Pain Therapeutics, Pfizer, Plexxikon, Prana, QR Pharma, Sanofi, Sonexa Therapeutics, Takeda Pharmaceutical, and Toyama Chemical. He also owns the copyright of the Neuropsychiatric Inventory and has provided expert witness consultation regarding olanzapine and ropinerol.